SOURCE: NuPathe Inc.

NuPathe Inc.

September 09, 2010 16:45 ET

NuPathe to Present at the Stifel Nicolaus 2010 Healthcare Conference

CONSHOHOCKEN, PA--(Marketwire - September 9, 2010) -  NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces that Jane Hollingsworth, chief executive officer, will present a company overview at the Stifel Nicolaus 2010 Healthcare Conference on Thursday, September 16, 2010 at 3:50 p.m. ET. The conference is being held at the Four Seasons Hotel in Boston.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company's website for one month following the call. 

About NuPathe

NuPathe Inc. is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's most advanced product candidate, Zelrix™, is a transdermal patch for the treatment of migraine. Zelrix actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin in a controlled manner using its proprietary SmartRelief™ technology.

In addition, NuPathe has two other proprietary product candidates in preclinical development that address large market opportunities: NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder. For more information, please visit NuPathe's website at www.nupathe.com.

Contact Information

  • Contact Information:

    Keith A. Goldan
    Vice President and Chief Financial Officer
    (484) 567-0130

    John Woolford
    Westwicke Partners, LLC
    (443) 213-0506